Chargement en cours...
Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High
Biosimilars are a highly anticipated arrival in the pharmacy. However, the undermanned and underfunded FDA struggles to guide, regulate, and approve them.
Enregistré dans:
| Publié dans: | P T |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MediMedia USA, Inc.
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4894512/ https://ncbi.nlm.nih.gov/pubmed/27313433 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|